Xience Stents Gain European Nod For Three-Month Dual Antiplatelet Therapy – Forbes
Xience Stents Gain European Nod For Three-Month Dual Antiplatelet Therapy Forbes Now the Xience Prime and Xience V everolimus-eluting stents have received the CE Mark in Europe for a DAPT length of only three months, according to an Abbott press release. The manufacturer of the stents, Abbott, said this was the “shortest duration ... |
Abbott’s XIENCE PRIME(TM) and XIENCE V® Drug Eluting Stents Receive Indication … – MarketWatch (press release)
Abbott's XIENCE PRIME(TM) and XIENCE V® Drug Eluting Stents Receive Indication ... MarketWatch (press release) PARIS, May 15, 2012 /PRNewswire via COMTEX/ -- Abbott (NYSE:ABT) today announced that the XIENCE PRIME(TM) and the XIENCE V® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for ... Abbott's XIENCE PRIME and XIENCE V Drug Eluting Stents Receive Indication in ... |
Hecoria, a Generic Tacrolimus for Transplant Recipients, Now Available by … – Gastroenterology & Endoscopy News
Hecoria, a Generic Tacrolimus for Transplant Recipients, Now Available by ... Gastroenterology & Endoscopy News Now available in US pharmacies, Hecoria is the first generic tacrolimus that can be prescribed by its brand name, according to its distributor, Novartis Pharmaceuticals. An AB-rated generic therapeutic bioequivalent to Prograf (tacrolimus capsules), ... |
Pharmaceutical companies such as Cipla, Sun Pharma deny wrongdoing in … – Economic Times
Pharmaceutical companies such as Cipla, Sun Pharma deny wrongdoing in ... Economic Times These drugs are Everolimus (Novartis), Colistimethate (Cipla)...," the panel pointed out while naming a few more companies. When contacted, a Cipla spokesperson said: "We have followed the procedure as laid down under the Drugs & Cosmetics Act for ... |
Prostate cancer drug ‘too expensive’ for NHS – Best Medical Cover
 Telegraph.co.uk | Prostate cancer drug 'too expensive' for NHS Best Medical Cover But the National Institute for Health and Clinical Excellence (NICE) deems the drug to be too pricy for use alongside prednisone or prednisolone as a second-line treatment for the disease. The final guidance means men will probably not be able to get ... NICE gives final rejection to Sanofi's Jevtana for prostate cancer |
UK’s NICE negative on Sanofi’s Jevtana, but backs Botox for migraine – The Pharma Letter
 Daily Mail | UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine The Pharma Letter The Appraisal Committee considered that the most plausible Incremental Cost Effectiveness Ratio (ICER) for cabazitaxel in combination with prednisone or prednisolone would be above £87500 ($141391) per QALY gained. The drug did meet the criteria to be ... NICE gives final rejection to Sanofi's Jevtana for prostate cancer |
Review finds 74% decline in annual ICU admissions for asthma – News-Medical.net
Review finds 74% decline in annual ICU admissions for asthma News-Medical.net "The main reason for the decline in cases is that more of our patients are taking their controller medications such as inhaled corticosteroids, which reduce the amount of inflammation in the airways," said lead author Jay I. Peters, MD, professor and ... |
SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows … – EON: Enhanced Online News (press release)
SYMBICORT® (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows ... EON: Enhanced Online News (press release) Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical ... |
Boston Scientific Announces Schedule For EuroPCR 2012 – Sacramento Bee
Boston Scientific Announces Schedule For EuroPCR 2012 Sacramento Bee EVOLVE is a prospective, randomized, non-inferiority trial that compares two dose formulations of everolimus on Boston Scientific's SYNERGY Coronary Stent System to the PROMUS Element™ Everolimus-Eluting Coronary Stent System in patients with de novo ... BOSTON SCIENTIFIC CORPORATION : Boston Scientific Announces Schedule For ... |
SYMBICORT(R) (budesonide/formoterol fumarate dihydrate)Long-Term Study Shows … – MarketWatch (press release)
SYMBICORT(R) (budesonide/formoterol fumarate dihydrate)Long-Term Study Shows ... MarketWatch (press release) Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical ... |